BR112018007681A2 - combinação farmacêutica de um antipsicótico atípico e um modulador de nmda para o tratamento de esquizofrenia, distúrbio bipolar, comprometimento cognitivo e distúrbio depressivo maior - Google Patents

combinação farmacêutica de um antipsicótico atípico e um modulador de nmda para o tratamento de esquizofrenia, distúrbio bipolar, comprometimento cognitivo e distúrbio depressivo maior

Info

Publication number
BR112018007681A2
BR112018007681A2 BR112018007681A BR112018007681A BR112018007681A2 BR 112018007681 A2 BR112018007681 A2 BR 112018007681A2 BR 112018007681 A BR112018007681 A BR 112018007681A BR 112018007681 A BR112018007681 A BR 112018007681A BR 112018007681 A2 BR112018007681 A2 BR 112018007681A2
Authority
BR
Brazil
Prior art keywords
disorder
cognitive impairment
schizophrenia
treatment
atypical antipsychotic
Prior art date
Application number
BR112018007681A
Other languages
English (en)
Inventor
Meltzer Hebert
R Moskal Joseph
Original Assignee
Univ Northwestern
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Northwestern filed Critical Univ Northwestern
Publication of BR112018007681A2 publication Critical patent/BR112018007681A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

esta invenção apresenta combinações de moduladores de nmda e antipsicóticos atípicos. a divulgação proporciona, por exemplo, métodos para tratar esquizofrenia, distúrbio bipolar e/ou distúrbio de comprometimento cognitivo num paciente em necessidade do mesmo compreendendo a administrar, por exemplo, rapastinel e um antipsicótico atípico.
BR112018007681A 2015-10-16 2016-10-14 combinação farmacêutica de um antipsicótico atípico e um modulador de nmda para o tratamento de esquizofrenia, distúrbio bipolar, comprometimento cognitivo e distúrbio depressivo maior BR112018007681A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562242633P 2015-10-16 2015-10-16
PCT/US2016/057071 WO2017066590A1 (en) 2015-10-16 2016-10-14 Pharmaceutical combination of an atypical antipsychotic and an nmda modulator for the treatment of schizophrenia,bipolar disorder, cognitive impairment and major depressive disorder

Publications (1)

Publication Number Publication Date
BR112018007681A2 true BR112018007681A2 (pt) 2018-11-06

Family

ID=57178579

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018007681A BR112018007681A2 (pt) 2015-10-16 2016-10-14 combinação farmacêutica de um antipsicótico atípico e um modulador de nmda para o tratamento de esquizofrenia, distúrbio bipolar, comprometimento cognitivo e distúrbio depressivo maior

Country Status (10)

Country Link
US (1) US20180325893A1 (pt)
EP (1) EP3362080A1 (pt)
JP (2) JP2018530593A (pt)
KR (1) KR20180102052A (pt)
CN (1) CN108601814A (pt)
AU (2) AU2016340080A1 (pt)
BR (1) BR112018007681A2 (pt)
CA (1) CA3002070A1 (pt)
MX (1) MX2018004553A (pt)
WO (1) WO2017066590A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4219507A3 (en) 2015-12-09 2023-08-16 Novartis AG Thienopyrimidinone nmda receptor modulators and uses thereof
EP3386591B1 (en) 2015-12-09 2020-06-24 Cadent Therapeutics, Inc. Heteroaromatic nmda receptor modulators and uses thereof
US11274107B2 (en) 2016-12-22 2022-03-15 Cadent Therapeutics, Inc. NMDA receptor modulators and uses thereof
AU2018367733B2 (en) 2017-11-14 2024-06-20 Sk Biopharmaceuticals Co., Ltd. Blend containing carbamate compound for prevention, mitigation, or treatment of schizophrenia
EA202190431A1 (ru) 2018-08-03 2021-06-11 Кэйдент Терапьютикс, Инк. Гетероароматические модуляторы nmda рецептора и их применение
US20220024976A1 (en) * 2019-01-11 2022-01-27 Naurex Inc. Salt and crystalline forms of rapastinel
KR20210060843A (ko) 2019-11-19 2021-05-27 뉴트라팜주식회사 기억력 및 인지기능 개선, 조현병 예방, 치료 또는 개선용 조성물

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5902815A (en) * 1996-09-03 1999-05-11 Washington University Use of 5HT-2A serotonin agonists to prevent adverse effects of NMDA receptor hypofunction
IL163725A0 (en) * 2002-02-25 2005-12-18 Elan Pharm Inc Administration of agents for the treatment of inflammation
SI1830833T1 (sl) * 2004-12-16 2010-05-31 Janssen Pharmaceutica Nv Kombinacija inhibitorja glicinskega transporterja GlyT in antipsihotika za zdravljenje simptomovshizofrenije in tudi njena priprava in njena uporaba
ES2707152T3 (es) * 2005-04-15 2019-04-02 Macrogenics Inc Diacuerpos covalentes y usos de los mismos
SI2485751T1 (sl) * 2009-10-05 2014-10-30 Northwestern University Glyx-13 za uporabo pri postopku za zdravljenje refraktorne depresije
KR101692275B1 (ko) * 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
US9101612B2 (en) * 2010-02-11 2015-08-11 Northwestern University Secondary structure stabilized NMDA receptor modulators and uses thereof
US9737531B2 (en) * 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
CN103974712A (zh) * 2011-04-27 2014-08-06 西北大学 治疗阿尔茨海默氏症、亨廷顿氏症、孤独症和其他障碍的方法
WO2013080046A1 (en) * 2011-12-02 2013-06-06 Dainippon Sumitomo Pharma Co., Ltd. Lurasidone novel dosage regimens and use thereof for the treatment, prevention, and/or management of at least one cns disorder
EP2906722A4 (en) * 2012-10-12 2016-07-20 Univ Northwestern METHODS OF IDENTIFYING COMPOUNDS FOR TREATING DEPRESSION AND OTHER ASSOCIATED DISEASES
CN111920412A (zh) * 2013-12-13 2020-11-13 西北大学 治疗脑部病症或鉴定与其相关的生物标记的方法
RU2721948C2 (ru) * 2014-05-06 2020-05-25 Нортвестерн Юниверсити Комбинации соединений, модулирующих nmda-рецептор
US20170296616A1 (en) * 2014-08-14 2017-10-19 Naurex, Inc. Methods of treating depression using nmda modulators

Also Published As

Publication number Publication date
WO2017066590A1 (en) 2017-04-20
CN108601814A (zh) 2018-09-28
CA3002070A1 (en) 2017-04-20
AU2023216827A1 (en) 2023-09-07
JP2018530593A (ja) 2018-10-18
MX2018004553A (es) 2019-04-15
RU2018116882A3 (pt) 2020-02-18
AU2016340080A1 (en) 2018-05-10
KR20180102052A (ko) 2018-09-14
US20180325893A1 (en) 2018-11-15
JP2022140441A (ja) 2022-09-26
EP3362080A1 (en) 2018-08-22
RU2018116882A (ru) 2019-11-18

Similar Documents

Publication Publication Date Title
BR112018007681A2 (pt) combinação farmacêutica de um antipsicótico atípico e um modulador de nmda para o tratamento de esquizofrenia, distúrbio bipolar, comprometimento cognitivo e distúrbio depressivo maior
ECSP19075354A (es) Moduladores de k-ras
UY37554A (es) (aza)indol- y benzofuran-3-sulfonamidas
BR112017002332A2 (pt) terapia de combinação para o tratamento de um paramixovírus
CL2018000684A1 (es) Moduladores de la proteína de núcleo de la hepatitis b.
GT201700246A (es) Métodos y kits para tratar la depresión
CL2018003265A1 (es) Modulares del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos.
BR112018001853A2 (pt) métodos para tratamento de um distúrbio e para melhoria do tratamento de um distúrbio
PH12017500494A1 (en) Methyl-and trifluoromethyl-substituted pyrrolopyridine modulators of rorc2 and methods of use thereof
AU2018348359A8 (en) Extended release pharmaceutical formulation and methods of treatment
EA201792157A1 (ru) Имидазопиразиноны в качестве ингибиторов pde1
CO2021014008A2 (es) Compuestos farmacéuticos para el tratamiento de trastornos mediados por complemento
BR112018070497A2 (pt) métodos e formulações farmacêuticas para tratamento de condições oculares
BR112017005313A2 (pt) formação de imagem e terapia para inflamação e infecção direcionadas por hsp90
BR112017024039B8 (pt) Piroglutamato de vortioxetina, composições farmacêuticas e gel compreendendo o mesmo, método para preparar um gel, e usos do piroglutamato de vortioxetina para fabricação de um medicamento ou gel
CO2017002356A2 (es) Métodos para tratar la depresión usando moduladores de nmda
CY1122784T1 (el) Αλογονωμενες κιναζολιν-τηf-αμινες ως αναστολεις του ρdε1
NZ734750A (en) Cancer therapy with a parvovirus combined with bevacizumab
EA201790893A1 (ru) Способы лечения офтальмологических расстройств
BR112019004067A2 (pt) catalisador de oxidação de metano, processo de preparar o mesmo e método de usar o mesmo
MX2017009164A (es) Moduladores de canales de ca2+ activados de liberacion de ca2+ (crac) y usos farmaceuticos de los mismos.
BR112019001130A2 (pt) uso de lactama e composição farmacêutica
BR112018076935A2 (pt) composição, medicamento e método para o tratamento da alopecia induzida por quimioterapia
BR112019004270A2 (pt) proteína livre de fenilalanina para o tratamento de pku
BR112022004645A2 (pt) Terapias combinadas com antibióticos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08G Application fees: restoration [chapter 8.7 patent gazette]